AI-assisted Rare Disease Diagnosis
NCT07650799
Disease, Disease Attributes
Beijing, China
View Trial DetailsNCT Number: NCT07130071
Rare diseases affect over 3.5 million people in the UK. It can take years of multiple referrals, inconclusive tests or incorrect diagnoses, for patients to get a final diagnosis. We call this diagnostic odyssey, and GPs are often the first point of call for patients at the start.
Algorithms can be used to help identify patients with rare diseases faster, who may benefit from testing. They also help healthcare professionals in decision making. Healthcare providers also recognise the value of quality improvement (QI) activities, but practices are often reluctant to participate in non-QOF QI initiatives.
CAPTURED aims to help reduce the diagnostic odyssey patients face by evaluating the efficiency of algorithms and tailored primary care QI support to identify, diagnose and refer patients with rare and difficult to diagnose disease. It will contribute towards these aspects of the UK Rare Disease Framework: (Priority 1) helping patients get a final diagnosis faster; and (Priority 2) increasing awareness of rare diseases among healthcare professionals.
CAPTURED will run as a stepped wedge, cluster randomised trial. Practices are the participants, and not individual patients. Practices will be randomly allocated to undertake quality improvement programmes (QIP) to help evaluate up to 10 rare disease algorithms. Practices will undertake QIPs at specific times, but at the end, all practices would undertake all the QIPs they have at-risk patients for. Practices will invite at-risk patients for testing/screening, and refer newly diagnosed patients for appropriate care. Practices will be supported with the QIPs by OPC Quality Improvement and Research Support Service, at no cost to practices.
CAPTURED will run for 5 years and will enrol 500 practices. The trial does not involve any medicine, drug or equipment. The trial will use anonymised patient data collected from all participating practices into the Optimum Patient Care Research Database (OPCRD).
Trial opening soon.
Get NotifiedAll sexes
Observational
The aim of CAPTURED is to evaluate the efficiency of algorithm technology and tailored primary care quality improvement support in identifying, testing and referring patients at high probability of specific rare or difficult to diagnose disease.
The trial aims to reduce the diagnostic odyssey for rare and difficult to diagnose disease patients and facilitate quicker access to appropriate treatment, utilising algorithms designed to identify patients that are at high probability.
CAPTURED is a series of quality improvement programs (QIPs) that are each delivered in a stepped wedge model, to enable comparison between the QI intervention and standard care. Each QIP, under CAPTURED, will utilise a specific algorithm for rare or difficult to diagnose disease, and a specific diagnostic testing/quality improvement support package. It is planned to run for 5 years (2025-2030). Each QIP will run for a defined period.
CAPTURED is UK-wide multicentre study. All participating practices should be able to accept the intervention (diagnostic test/screening and tailored quality improvement support package) as part of their patient care. CAPTURED will be conducted at an estimated 500 GP practices in the UK. Only practices with patients identified as at high probability of specific rare or difficult to diagnose disease will participate in each project. The algorithms use digital biomarkers in patients electronic medical record data such as symptoms, diagnoses and healthcare utilisation to identify patients who would benefit from specific diagnostic testing. Individual projects will have specific cut-offs to determine high probability of disease but typically it is a likelihood of 60% or more.
Practices with patients with high probability of disease will be randomised into clusters. Randomisation will occur individually for each QIP. The intervention (diagnostic testing/screening and quality improvement support package) will be given at different time-points defined by the stepped wedge design.
The index date (time = 0) will be defined as the date that the first cluster of practices receives communication about having patients identified as at high probability of rare or difficult to diagnose disease. Communication with remaining clusters will be sent out at the exact time points defined by the stepped wedge design but will be specific to each project.
The primary objective of CAPTURED is to demonstrate that the patient testing pathway works defined as:
The secondary objectives of the trial are outlined below:
The following exploratory objectives will be explored as part of the trial:
Results for all projects (up to 10) will be combined for overall analysis of CAPTURED at the end of the 5-year planned trial period.
The algorithm for each QIP will be run at baseline on the Optimum Patient Care Research Database (OPCRD) and the Optimum Patient Care Research Database (OPCSD), to identify practices with patients who are at high probability of disease. Only practices (and their patients) that fulfil the inclusion criteria and none of the exclusion criteria will be included. Initially, practices with a population of at least 15,000 patients will be included, to maximise likelihood of identifying patients at high probability of disease. This is a flexible cut-off that can be removed depending on numbers of patients identified. Practices that have no current high probability patients for a particular QIP will be excluded from that QIP only but will remain in the CAPTURED overarching trial and eligible for further QIPs.
Participating practices will be offered quality improvement support which will include specific diagnostic testing. Exact details of quality improvement support provided will be determined by each QIP and will all comprise the following core activities:
These are patient care activities and are NOT research activities.
The specific diagnostic testing process may be remote (e.g. delivered to patients), at practice or at a specified test centre; and will be determined by each QIP.
Once testing has been completed, the patient and GP practice are informed of the result and supported with further steps, as required. Anonymised patient data from participating practices will be collected for trial analysis.
Evaluation of CAPTURED will occur at the end of the 5-year study period.
Practices will be considered as in the control phase in the pre-intervention window. Once randomisation occurs practices move from control to intervention at different points in time. So, all practices contribute some data to both control and intervention periods. Thus, the comparison is those control periods versus those intervention periods.
The proposed study population will be GP practices with patients flagged by the algorithm(s) in the Optimum Patient Care Research Database (OPCRD) and the Optimum Patient Care Service Database (OPCSD). The OPCRD is a REC approved, longitudinal electronic medical record database of over 29 million patients in the UK that is established and managed by Optimum Patient Care Ltd (OPC). OPCSD is pseudonymised patient database used to provide ongoing quality improvement services and programmes to GP practices across the UK.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Rate of patients given diagnosis for rare or difficult to diagnose disease in intervention population compared to rate of patients given diagnosis for rare or difficult to diagnose disease in control population, in a comparable time frame who receive delayed roll out, by way of a step wedge implementation .
Definition: Direct comparison between (1) Total number of patients who are positively diagnosed as a direct result of the intervention in the intervention population/whole patient population for intervention population and (2) Total number of patients who are positively diagnosed in the control population/whole patient population for the control population.
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Rate of patients successfully completing diagnostic testing/screening in intervention population compared to control population, in a comparable time frame who receive delayed roll out, by way of a step wedge implementation .
Definition: Direct comparison between (1) Total number of patients who successfully complete diagnostic testing as a direct result of the intervention in the intervention population and (2) Total number of patients who successfully complete diagnostic testing in control population in a comparable time frame who receive delayed roll out, by way of a step wedge implementation .
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Rate that patients are successfully contacted about testing/screening = total number of patients identified by the algorithm who are successfully contacted about testing/screening / number of patients identified by the algorithm deemed eligible for testing after practice and medical review.
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Rate that patients agree to testing/screening = total number of patients identified by the algorithm who are successfully contacted about testing/screening AND agree to testing or screening/number of patients identified by the algorithm with who attempted contact is made.
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Proportion of patients the algorithm identified deemed clinically appropriate for testing, defined by Medical professional judgement = number of patients identified by algorithm as high-risk deemed clinically appropriate for testing following review by Medical Professional/number of patients identified by the algorithm as high-risk that undergo review by Medical professional.
Time frame: Each individual QIP will have a defined time-frame as per the stepped-wedge design. Anonymised data of patients will be collected throughout the project for each participating practice. Results will be analysed at the end of the 5-year trial period.
Results of diagnostic testing will be recorded, regardless of result. This will include positive and negative results for specific diseases that the algorithm is identifying patients for and also any alternative diagnoses derived from the quality improvement process.
Contact information is provided by the study sponsor or research team.
Francis Appiagyei
CONTACT
Victoria Carter
CONTACT
Research in Real-Life Ltd
Network
A Pragmatic, Stepped Wedge, Multi-centre, Cluster Randomised Trial Evaluating the Efficiency of Algorithm Technology and Tailored Primary Care Quality Improvement Support to Identify, Diagnose and Refer Patients With Rare and Difficult to Diagnose Disease (Defined by the NHS as Those Suffering From Significant Diagnostic Odyssey)
Acronym: CAPTURED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07650799
Disease, Disease Attributes
Beijing, China
View Trial DetailsNCT07625436
Disease, Disease Attributes
Beijing, China
View Trial DetailsNCT06656247
Behavior, Disease Attributes
View Trial DetailsNCT06729554
Disease Attributes, Inborn Errors of Metabolism Disorders
Graz, Austria
View Trial Details